Condensed Consolidated Statements of Operations (Unaudited) - USD ($) |
3 Months Ended | 9 Months Ended | ||
|---|---|---|---|---|
Sep. 30, 2020 |
Sep. 30, 2019 |
Sep. 30, 2020 |
Sep. 30, 2019 |
|
| Total revenue | $ 4,298,000 | $ 3,618,000 | $ 15,348,000 | $ 16,073,000 |
| Operating expenses: | ||||
| Research and development | 19,622,000 | 15,249,000 | 70,667,000 | 33,946,000 |
| General and administrative | 7,547,000 | 4,509,000 | 19,606,000 | 14,049,000 |
| Loss on impairment of in-process research and development | 0 | 22,123,000 | 0 | 22,123,000 |
| Total operating expenses | 27,169,000 | 41,881,000 | 90,273,000 | 70,118,000 |
| Loss from operations | 22,871,000 | 38,263,000 | 74,925,000 | 54,045,000 |
| Interest and other income, net | 167,000 | 396,000 | 925,000 | 1,449,000 |
| Interest and other expense, net | (521,000) | (353,000) | (1,229,000) | (947,000) |
| Loss on extinguishment of debt | 0 | 0 | (1,237,000) | 0 |
| Change in fair value of warrant liabilities | 0 | 1,000 | 0 | 3,000 |
| Loss before provision for income taxes | 23,225,000 | 38,219,000 | 76,466,000 | 53,540,000 |
| Provision for income taxes | 0 | 0 | 5,000 | 0 |
| Net loss | 23,225,000 | 38,219,000 | 76,471,000 | 53,540,000 |
| Net loss attributable to common shareholders | $ 23,225,000 | $ 38,219,000 | $ 76,471,000 | $ 53,540,000 |
| Net loss per share attributable to common shareholders: | ||||
| Basic and diluted | $ 0.47 | $ 1.03 | $ 1.63 | $ 1.45 |
| Weighted average number of shares used in net loss per share calculations: | ||||
| Basic and diluted | 49,026,499 | 36,937,912 | 46,808,437 | 36,832,966 |
| Research And Development Revenue | Other | ||||
| Total revenue | $ 2,732,000 | $ 284,000 | $ 7,176,000 | $ 284,000 |
| Research And Development Revenue | Related Party | ||||
| Total revenue | 1,566,000 | 2,903,000 | 4,962,000 | 14,527,000 |
| Grant | ||||
| Total revenue | $ 0 | $ 431,000 | $ 3,210,000 | $ 1,262,000 |
| X | ||||||||||
- Definition Interest and other expense net. No definition available.
|
| X | ||||||||||
- Definition Loss on impairment of in process research and development. No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount of expense (income) related to adjustment to fair value of warrant liability. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The net amount of nonoperating interest income (expense). No definition available.
|
| X | ||||||||||
- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The net result for the period of deducting operating expenses from operating revenues. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of revenue from collaborative arrangement. Excludes revenue from contract with customer under Topic 606. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS). No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|